GPO: Medicine Stocks Stable Despite Middle East Tensions

The Government Pharmaceutical Organisation (GPO) reports that the recent Middle East unrest has not impacted its pharmaceutical and raw material reserves, ensuring continued production and supply. Dr. Mingkwan Supphannapong, GPO's director, confirmed on Monday that the organisation is monitoring the situation and has implemented robust procurement and production plans. An inspection of inventories indicates a one-year reserve of essential materials and medicines.

Get today's headlines by email

The GPO produces medicines domestically, sourcing raw materials from unaffected regions like India, Japan, China, and Europe. They transport supplies via sea and air, relying on advance procurement strategies to secure a stable supply chain. The injectable drug trastuzumab, sourced from Iran with an annual use of about 29,000 vials, has confirmed availability until October, with alternatives from India, South Korea, and Europe ready if necessary.

Dr. Mingkwan assures that operations remain stable, with coordination with international manufacturers and continual adjustments to procurement strategies ensuring uninterrupted production. The primary goal is securing national pharmaceutical needs and maintaining public access to essential treatments. Proactive management is key to adjusting plans as global conditions evolve, reported Bangkok Post.

Join the discussion?

Already a member?

  Adapted by ASEAN Now · Bangkok Post · 03 Mar 2026